Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin
US FDA Clears Monotherapy Use
Executive Summary
At ESMO, data showed objective response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.
You may also be interested in...
Keytruda Expands Cervical Cancer Position With ESMO Data
In addition to securing a key position in first-line disease, Keytruda has potential to expand its presence in later lines with combination data from Seagen/Genmab’s Tivdak.
GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
GlaxoSmithKline Survives Technical Woes To Win US FDA Panel Nod For Belantamab
Benefits of the BCMA-directed antibody-drug conjugate outweigh its ocular risks in heavily pretreated multiple myeloma patients, Oncologic Drugs Advisory Committee says at the conclusion of a virtual meeting beset by technical problems.